Microscopy Image Analysis for Cellular Disease Model Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional patient treatments are inefficient and costly, and the development of new therapeutics is slow and resource-intensive due to insufficient understanding of genetic and environmental factors contributing to disease onset, leading to inconsistent safety and efficacy profiles in clinical trials.
Innovation Solution
Development of machine-learning-enabled cellular disease models that utilize trained machine learning models to analyze phenotypic assay data from genetically engineered cells, predicting clinical outcomes and identifying therapeutic interventions, patient populations, and biological targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional patient treatments and therapeutic development methods are used, then understanding of genetic basis for diseases is obtained, but treatment effectiveness remains insufficient and development costs remain high
Solution Approach 1:
The patent creates in vitro cellular models that replicate human disease states, allowing researchers to study and test treatments on cell cultures that copy human pathology. These cellular models serve as substitutes for human patients in preclinical research, enabling reliable treatment effectiveness assessment without requiring extensive human clinical trials at early stages, thereby reducing development costs while maintaining reliability.
Solution Approach 2:
The patent employs machine learning models trained on extensive phenotypic data to predict treatment outcomes before clinical trials. By performing preliminary computational analysis and in vitro screening on cellular models, the system identifies promising therapeutic candidates in advance, reducing the need for costly and time-consuming failed clinical trials and improving overall treatment effectiveness through better candidate selection.
2Reliability
If new therapeutics are developed through conventional methods, then genetic understanding is improved, but development speed remains slow
Solution Approach 1:
The patent replaces traditional mechanical and time-consuming methods of therapeutic development with machine learning algorithms and automated phenotypic analysis systems. The machine learning models rapidly analyze complex phenotypic data from cellular models to predict treatment outcomes, substituting slow conventional trial-and-error approaches with fast computational prediction, thereby accelerating development speed while maintaining therapeutic efficacy through data-driven decision making.
Solution Approach 2:
The patent creates self-service systems where machine learning models automatically analyze phenotypic data and predict treatment outcomes without extensive human intervention. The system uses automated image analysis and computational algorithms to evaluate cellular responses to treatments, enabling rapid screening of multiple therapeutic candidates simultaneously, thus improving development speed while ensuring reliable efficacy predictions through consistent automated assessment.
3Measurement precision
If comprehensive phenotypic analysis is performed to improve treatment prediction accuracy, then measurement precision is improved, but system complexity increases
Solution Approach 1:
The patent extracts and focuses on specific key phenotypic features that are most predictive of treatment outcomes, rather than attempting to analyze all possible cellular characteristics. The machine learning models are trained to identify and measure only the most relevant phenotypic markers, reducing model complexity while maintaining high measurement precision for the critical features that drive treatment response prediction.
Solution Approach 2:
The patent applies different levels of analysis depth to different phenotypic features based on their predictive value. Instead of uniformly complex analysis across all parameters, the system concentrates sophisticated machine learning analysis on specific phenotypic measurements that have been shown to correlate strongly with treatment outcomes, while using simpler methods for less critical features, thus optimizing the balance between measurement precision and system complexity.
Data Source
AI summary
Embodiments of the disclosure include systems and non-transitory computer readable media for analyzing microscopy images for developing machine learning models for disease modeling. Microscopy images are captured from cells of one or more exposure response phenotypes (ERPs) and further used to train machine learning models. Thus, trained machine learning models can distinguish between microscopy images captured from healthy and diseased samples.